Encompass Health (NYSE:EHC) Sets New 52-Week High at $86.85

Encompass Health Co. (NYSE:EHC - Get Free Report)'s stock price hit a new 52-week high during trading on Monday . The company traded as high as $86.85 and last traded at $86.72, with a volume of 19982 shares. The stock had previously closed at $86.53.

Wall Street Analysts Forecast Growth

EHC has been the topic of several recent analyst reports. Barclays boosted their target price on shares of Encompass Health from $101.00 to $108.00 and gave the company an "overweight" rating in a report on Thursday, April 25th. Mizuho boosted their target price on shares of Encompass Health from $93.00 to $95.00 and gave the company a "buy" rating in a report on Thursday, April 25th. Stephens restated an "overweight" rating and issued a $85.00 target price on shares of Encompass Health in a report on Tuesday, January 16th. Royal Bank of Canada reiterated an "outperform" rating and set a $83.00 price objective on shares of Encompass Health in a report on Friday, February 9th. Finally, Truist Financial upped their price objective on shares of Encompass Health from $82.00 to $86.00 and gave the company a "buy" rating in a report on Friday, February 9th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $90.29.

Encompass Health Stock Down 0.4 %

The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.37. The firm's fifty day moving average price is $80.24 and its two-hundred day moving average price is $72.46. The stock has a market cap of $8.68 billion, a price-to-earnings ratio of 23.39, a price-to-earnings-growth ratio of 1.35 and a beta of 0.92.

Encompass Health (NYSE:EHC - Get Free Report) last posted its earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.93 by $0.19. The company had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The firm's revenue for the quarter was up 13.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.88 earnings per share. Sell-side analysts forecast that Encompass Health Co. will post 4.09 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Friday, June 28th. Encompass Health's payout ratio is presently 16.22%.

Insider Transactions at Encompass Health

In other news, Director Greg D. Carmichael acquired 2,000 shares of Encompass Health stock in a transaction on Friday, May 3rd. The stock was acquired at an average cost of $83.73 per share, with a total value of $167,460.00. Following the transaction, the director now owns 17,050 shares of the company's stock, valued at approximately $1,427,596.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Greg D. Carmichael bought 2,000 shares of Encompass Health stock in a transaction dated Friday, May 3rd. The stock was purchased at an average cost of $83.73 per share, with a total value of $167,460.00. Following the transaction, the director now directly owns 17,050 shares of the company's stock, valued at $1,427,596.50. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now directly owns 554,098 shares of the company's stock, valued at $46,139,740.46. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by insiders.

Institutional Trading of Encompass Health

Institutional investors have recently modified their holdings of the business. O Shaughnessy Asset Management LLC lifted its stake in Encompass Health by 3.9% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 4,246 shares of the company's stock worth $351,000 after purchasing an additional 160 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its stake in Encompass Health by 44.8% in the 1st quarter. Ontario Teachers Pension Plan Board now owns 59,835 shares of the company's stock worth $4,941,000 after purchasing an additional 18,520 shares in the last quarter. Vanguard Group Inc. lifted its stake in Encompass Health by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 10,166,147 shares of the company's stock worth $839,520,000 after purchasing an additional 169,113 shares in the last quarter. Trillium Asset Management LLC purchased a new stake in Encompass Health in the 1st quarter worth approximately $4,432,000. Finally, Scout Investments Inc. purchased a new stake in Encompass Health in the 1st quarter worth approximately $29,356,000. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.